ArticleEuropean radiology2024
Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([
Article in European radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 10 citations in OpenAlex.
- Association of SUVmax and never-smoker/never- or minimally-drinker history with PD-L1 expression in resected oral squamous cell carcinoma: a nodal-status-stratified analysis.Annals of nuclear medicine · 2026Article
- Integrating Lymph Node Metastasis and Programmed Death-Ligand 1 Prediction in Non-Small Cell Lung Cancer From a Single PET/CT Scan: Multicenter Radiomics Study.JMIR medical informatics · 2026Article
- Article
- Independent Testing of Published CT Models for PD-L1 Status in Non-Small Cell Lung Cancer.Radiology · 2026Article
- Comparative evaluation of machine learning models for predicting PD-L1 high expression in resectable NSCLC: a dual-center study integrating [Frontiers in immunology · 2026Article
- Enhanced glucose uptake promotes the survival of hepatocellular carcinoma cells following incomplete radiofrequency ablation.Molecular & cellular oncology · 2026Article
- Noninvasive Prediction of Programmed Cell Death Protein-Ligand 1 Expression in Locally Advanced Non-small Cell Lung Cancer byAnnals of surgical oncology · 2025Article
- Article
- Recent advances in theranostics and oncology PET: emerging radionuclides and targets.Annals of nuclear medicine · 2025Review
- Comparison of standardized uptake value and standardized uptake lean body mass metrics inQuantitative imaging in medicine and surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundProgrammed death-ligand 1 (PD-L1) expression is a predictive biomarker for immunotherapy in non-small cell lung cancer (NSCLC). PD-L1 and glucose transporter 1 expression are closely associated, and studies demonstrate correlation of PD-L1 with glucose metabolism.
aimThe aim of this study was to investigate the association of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ([
methodsWe conducted a retrospective analysis of 210 patients with node-positive resectable stage IIB-IIIB NSCLC. PD-L1 tumour proportion score (TPS) was determined using the DAKO 22C3 immunohistochemical assay. Semi-automated techniques were used to analyse pre-operative [
resultsPatients were predominantly male (57%), median age 70 years with non-squamous NSCLC (68%). A majority had negative primary tumour PD-L1 (TPS < 1%; 53%). Mean SUV
conclusionThis study demonstrated the association of SUV-based [ CLINICAL RELEVANCE STATEMENT: Whilst SUV-based fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography metabolic parameters may not predict programmed death-ligand 1 positivity ≥ 1% in the primary tumour and lymph nodes of resectable non-small cell lung cancer independently, there is a clear association which warrants further investigation in prospective studies.
trial registrationNon-applicable KEY POINTS: • Programmed death-ligand 1 immunohistochemistry has a predictive role in non-small cell lung cancer immunotherapy; however, it is both heterogenous and dynamic. • SUV-based fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography ([
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.